List view / Grid view
6 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
NICE has issued a final appraisal determination recommending that venclyxto is made available to patients with chronic lymphocytic leukaemia...
26 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
EvaluateMedTech World Preview provides a range of insights into the expected performance of the medtech industry...
22 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
6 June 2017 | By Niamh Marriott, Junior Editor
The FDA have approved Roche’s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients...
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
5 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma...
4 May 2017 | By Niamh Marriott, Junior Editor
Roche’s new, dedicated high-volume testing immunoassay solution for the cobas 8000 modular analyser series, the cobas e 801 module, has received 510(k) clearance from the US Food and Drug Administration (FDA). As core laboratories continue to evolve to meet the growing workload demands in an increasingly challenging environment, the cobas…
12 April 2017 | By Alexandra Kibble (Senior Editor - Clarivate Analytics Cortellis)
The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of more than $900 billion by 2021...
6 February 2017 | By Niamh Marriott (European Pharmaceutical Review)
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
10 January 2017 | By Niamh Marriott, Digital Editor
The blood test produces standardised results for assessing ovarian reserve as compared with the use of vaginal ultrasound...
29 December 2016 | By Niamh Louise Marriott, Digital Editor
Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should...
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A discount to the price of pertuzumab agreed with the company was an important factor in enabling NICE to overturn its earlier provisional decision...
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries...
11 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Prothena’s Phase 1b multiple ascending dose study of PRX002 trial found an acceptable safety and tolerability profile in patients with Parkinson’s disease...
31 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC). The PD-L1 (SP142) assay is also indicated to identify patients with urothelial cancer (UC)…
Send this to a friend
Follow: